Company: SCLXW
Filing Date: 2025-11-04
Form Type: 424B3
Source: 0001193125-25-264321
Chunk: 25

Company: Scilex Holding Co
Filing Date: 2025-11-04
Form: 424B3
Chunk 25
---
 trading of biotech data assets while maintaining compliance and privacy standards.

According to the licensing agreement, Scilex shall pay a non-refundable upfront license fee in four equal installments of $2.5 million each on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. DataVault will earn sales milestone payments of up to an aggregate of $2.55 billion upon the achievement of certain applicable sales milestones.

For more information on Scilex Holding Company, refer towww.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer towww.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer towww.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer towww.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer towww.gloperba.com.

<div align='center'>Page |35</div>

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA�